A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia

PHASE3CompletedINTERVENTIONAL
Enrollment

848

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Community-Acquired Bacterial PneumoniaLung Infection of Individual Not Recently Hospitalized
Interventions
DRUG

Ceftaroline

Two consecutive infusions q12h for 5 to 7 days

DRUG

Ceftriaxone

One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.

Trial Locations (43)

Unknown

Research Site, Beijing

Research Site, Chengdu

Research Site, Guangzhou

Research Site, Haikou

Research Site, Hangzhou

Research Site, Hefei

Research Site, Jiangyin

Research Site, Nanchang

Research Site, Shanghai

Research Site, Shenyang

Research Site, Shenzhen

Research Site, Shijiazhuang

Research Site, Wuxi

Research Site, Bangalore

Research Site, Calicut

Research Site, Goa

Research Site, Hyderabad

Research Site, Jaipur

Research Site, Lucknow

Research Site, Ludhiana

Research Site, Mysore

Research Site, New Delhi

Research Site, Trivandrum

Research Site, Varanasi

Research Site, Vellore

Research Site, Anyang-si

Research Site, Bucheon-si

Research Site, Cheonan-si

Research Site, Chuncheon

Research Site, Daegu

Research Site, Daejeon

Research Site, Incheon

Research Site, Seoul

Research Site, Suwon

Research Site, Wŏnju

Research Site, Kaohsiung City

Research Site, Keelung

Research Site, Taichung

Research Site, Taipei

Research Site, Can Tho

Research Site, Hanoi

Research Site, Ho Chi Minh City

Research Site, Hochiminh

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Pfizer

INDUSTRY